What it is
Telavancin is a lipoglycopeptide: vancomycin's glycopeptide core with two additions — a fatty decylaminoethyl chain and a phosphonomethyl-aminomethyl group. That is how the Vibativ label's chemical name reads ("vancomycin, N3''-[2(decylamino)ethyl]-29-[[(phosphonomethyl)amino]methyl]"), and the label calls it "a synthetic derivative of vancomycin". The core is a short chain of seven amino acids, cross-linked into a rigid cup and decorated with sugars, which is why the drug sits in this library.
| Property | Value | Source |
|---|---|---|
| Formula | C80H106Cl2N11O27P | PubChem CID 3081362 |
| Molecular weight | 1,755.6 | PubChem |
| Class | Lipoglycopeptide antibacterial | Label section 11 |
| Made from | Vancomycin (semi-synthetic) | Label |
| Route | Intravenous infusion over 60 minutes | Label section 2 |
How it acts. The label's microbiology section gives two actions: telavancin "inhibits cell wall biosynthesis by binding to late-stage peptidoglycan precursors, including lipid II", and it "binds to the bacterial membrane and disrupts membrane barrier function". The first is the action it shares with its parent; the second is what the label adds for telavancin.
Its relatives in the library. Vancomycin is the parent. Two other approved lipoglycopeptides carry their own entries: dalbavancin and oritavancin.
What the trials showed
Skin infections. The label reports two identical randomised, double-blind trials comparing telavancin 10 mg/kg once daily with vancomycin 1 g twice daily for 7 to 14 days in adults with complicated skin and skin-structure infections where MRSA was suspected or confirmed. The all-treated population was 1,794 patients; major abscess (42–44%) and deep or extensive cellulitis (35–37%) made up about three in four infections (label Table 9).
| Population | Trial 1: telavancin | Trial 1: vancomycin | Trial 2: telavancin | Trial 2: vancomycin |
|---|---|---|---|---|
| All treated | 72.5% (309/426) | 71.6% (307/429) | 74.7% (342/458) | 74.0% (356/481) |
| Clinically evaluable | 84.3% (289/343) | 82.8% (288/348) | 83.9% (302/360) | 87.7% (315/359) |
Read across the table, the cure rates sit within a few points of vancomycin in every cell; in the clinically evaluable group of Trial 2, vancomycin's figure is the higher one.
Hospital and ventilator pneumonia. Two further identical trials compared the same regimens for 7 to 21 days. The label states that all-cause mortality was evaluated "because there is historical evidence of treatment effect for this endpoint". Its Table 12 gives 28-day mortality in patients with at least one Gram-positive respiratory pathogen:
| Group | Trial 1: telavancin | Trial 1: vancomycin | Trial 2: telavancin | Trial 2: vancomycin |
|---|---|---|---|---|
| All patients | 28.7% (N=187) | 24.3% (N=180) | 24.3% (N=224) | 22.3% (N=206) |
| CrCl ≤ 50 mL/min | 41.8% (N=63) | 35.4% (N=68) | 43.9% (N=53) | 29.6% (N=58) |
| CrCl > 50 mL/min | 22.0% (N=124) | 17.6% (N=112) | 18.2% (N=171) | 19.3% (N=148) |
The kidney-impairment row is the source of the boxed warning: in both trials more patients with poor kidney function died on telavancin, by 6.4 and 14.3 percentage points. The confidence intervals the label prints for those differences both cross zero, so each trial alone does not establish the gap; the label's warning rests on the pattern, and the label reserves the pneumonia use for when alternatives are not suitable.
What is not established: any advantage over vancomycin in cure rate, and any use outside the two labelled infection types.
Risks the label lists
- Boxed warning: increased mortality in pneumonia patients with creatinine clearance of 50 mL/min or less; new-onset or worsening kidney impairment (kidney function is monitored in all patients); possible fetal harm, from animal reproduction studies.
- Common reactions: taste disturbance, nausea, vomiting and foamy urine in the skin-infection trials; diarrhoea in the pneumonia trials (10% or more of patients).
- Other warnings: infusion-related reactions (hence the 60-minute infusion), Clostridioides difficile-associated diarrhoea, and QTc prolongation, with the label advising avoidance in patients at risk.
Where it stands
Telavancin is a prescription hospital antibiotic in the US. Drugs@FDA holds two Vibativ applications — NDA 022110, original approval 11 September 2009, and NDA 022407, original approval 21 June 2013 — and on 2026-11-20 listed one Vibativ product as discontinued and the rest as prescription products; this entry does not infer why. The current label, effective 19 December 2025, names Cumberland Pharmaceuticals as the company to report adverse reactions to. The label dose is 10 mg/kg once every 24 hours, adjusted to 7.5 mg/kg every 24 hours at a creatinine clearance of 30–50 mL/min and lowered further below that.
Other peptide antibiotics in the library work differently: daptomycin is a lipopeptide that disrupts the membrane, and polymyxin B targets Gram-negative bacteria that telavancin does not cover.
Sources opened 2026-11-20: Vibativ label (openFDA, effective 2025-12-19: sections 1, 2, 5, 6, 11, 14 incl. Tables 9, 10, 12); Drugs@FDA records for NDA 022110 and NDA 022407; PubChem CID 3081362 (properties); PubMed E-utilities and ClinicalTrials.gov API v2 counts.
